In selecting 9‐ING‐41 (Elraglusib) for our study, we considered its unique profile as a reversible ATP‐competitive GSK‐3 inhibitor that has shown significant inhibition of GSK‐3β activity and preclinical antitumor activity in several cancers, including pancreatic and bladder cancers [45, 72, 73]. This evidence concerns the gene GSK3B and urinary bladder cancer.